Advertisements

In-vitro Diagnostic Services Market to Perceive Substantial Growth during 2019-2023

In-vitro Diagnostic Services Market 2019 Report analyses the Industry Status, Size, Share, Emerging Trends, Growth Opportunity, Competition landscape and Forecast to 2023. This report also provides data on Patterns, Improvements, Target Business Sectors, Limits and Advancements.

Global In-vitro Diagnostic Services Market overview:

The report ” In-vitro Diagnostic Services Market” The quick adoption of advanced Analytics and Visualization and the expand use of outward data sources are the major drivers of the In-vitro Diagnostic Services Market. The report high Point, Potential Growth Opportunities in the coming years and covers a review of the Market Drivers, Growth Measure, Competitive Landscape, Market Dynamics, Opposition and other In-vitro Diagnostic Services Feature to the In-vitro Diagnostic Services Market.

Get sample of the report@ https://www.businessindustryreports.com/sample-request/192630.

According to Market Analyst, Global In-vitro Diagnostic Services Market is projected to grow at a healthy growth rate from 2019 to 2023.

The Global In-vitro Diagnostic Services Market is segmented on the basis of Product Type, Application, End Use Industry and Region. On the Basis of Product Type segment, the In-vitro Diagnostic Services Market is sub segmented into Infectious Testing, Diabetes Testing, Molecular Testing, Tissue Testing. Based on End Use Industry segment, the In-vitro Diagnostic Services Market is sub segmented into Hospitals, Point-Of-Care Testing, Laboratories, Academic Institutes.

Some of the major players that operate in the Global In-vitro Diagnostic Services Market are BioRad, DexCom, Nova Biomedical, OraSure, Pearl Pathways, Phenomenex, Qiagen, Roche Diagnostics, Siemens, Sysmex, Thermofisher.

We Can also provide the customized separate regional or country-level reports, for the following regions: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC) and all over the world.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Latest Industry Updates:

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has filed a patent infringement suit against 10X Genomics, Inc. in the United States District Court for the District of Delaware.

In the lawsuit Bio-Rad asserts that 10X Genomics infringes U.S. Patent No. 8,871,444, which is exclusively licensed to Bio-Rad from Harvard University and the Medical Research Council. This patent covers techniques for detecting enzymatic reactions in microfluidic droplets and is part of Bio-Rad’s comprehensive portfolio of droplet intellectual property. The suit asserts that 10X Genomics infringes through the sale of its recently-announced Next GEM family of products. As stated in Bio-Rad’s Complaint, Harvard University is joined in the case as a nominal defendant solely for the legal purposes of jurisdiction and standing. Bio-Rad is seeking all available remedies against 10X Genomics, including damages and injunctive relief.

The suit filed today is Bio-Rad’s third action against 10X Genomics in Delaware District Court and its second action that is directed to 10X’s Next GEM products. In November 2018, a Delaware jury found that 10X Genomics infringed patents licensed to Bio-Rad by the University of Chicago and awarded damages of $23.9M. In August 2019, the Delaware Court awarded Bio-Rad an additional $10.5 M in supplemental damages and interest and entered a permanent injunction against 10X Genomics.

“Bio-Rad will continue to grow and protect its portfolio of patents in the droplet microfluidics space that deliver differentiated genomics technologies and enable world class research,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer.

Get Attractive Discount @ https://www.businessindustryreports.com/check-discount/192630.

Table of Contents:

Global In-vitro Diagnostic Services Market Report 2019

Section 1 In-vitro Diagnostic Services Product Definition

Section 2 Global In-vitro Diagnostic Services Market Manufacturer Share and Market Overview

2.1 Global Manufacturer In-vitro Diagnostic Services Shipments

2.2 Global Manufacturer In-vitro Diagnostic Services Business Revenue

2.3 Global In-vitro Diagnostic Services Market Overview

Section 3 Manufacturer In-vitro Diagnostic Services Business Introduction

3.1 BioRad In-vitro Diagnostic Services Business Introduction

3.1.1 BioRad In-vitro Diagnostic Services Shipments, Price, Revenue and Gross profit 2014-2018

3.1.2 BioRad In-vitro Diagnostic Services Business Distribution by Region

3.1.3 BioRad Interview Record

3.1.4 BioRad In-vitro Diagnostic Services Business Profile

3.1.5 BioRad In-vitro Diagnostic Services Product Specification

………………. Request sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

Advertisements

Leave a Reply

%d bloggers like this: